Krebsmedikament: Neue Therapie gegen tödliche Krebsform – Was bringt sie?
Ein neues Medikament verlängert laut einer Studie das Leben von Menschen mit fortgeschrittenem Bauchspeicheldrüsenkrebs, verspricht aber keine Heilung. Nun ist die Zulassung in Europa ein Stück näher.
Pancreatic cancer is a dreaded diagnosis, often diagnosed late with poor survival rates. A new drug, Daraxonrasib, offers hope for advanced-stage patients, potentially extending survival compared to chemotherapy. The European Medicines Agency (EMA) recommends the drug for EU approval in adults with pancreatic cancer that has metastasized and previously undergone treatment.
The drug, known as Rasonque, targets tumors with an active tumor suppressor protein. In a phase-III study, patients on Daraxonrasib lived, on average, 12.4 months versus 6.7 months for those on chemotherapy. The drug belongs to a new class of drugs called RAS(ON)-inhibitors, which inhibit the interaction between the RAS protein and downstream signaling pathways.
RAS is a proto-oncogene that, when permanently active due to mutations, promotes tumor growth. Daraxonrasib is effective against multiple RAS variants, not just a specific mutation. Side effects were common but generally mild, with serious adverse events occurring less frequently than with chemotherapy. The drug's effectiveness may extend to other cancers with similar mutations, and trials for other cancer types are underway.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
